Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) [Phase 1]

View source ↗

Summary

The COBALT-LYM Phase 1 trial evaluating CTX130 in relapsed or refractory T- or B-cell malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies
• T-cell Lymphoma

Drugs mentioned

• CTX130

Snippet

Sponsor: CRISPR Therapeutics AG | Conditions: T Cell Lymphoma | Phase 1 | Status: TERMINATED